Investigational Drug Information for AT7519
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug AT7519?
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 24th 2012.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Mantle-Cell, and Leukemia, Lymphoid. The leading clinical trial sponsors are NCIC Clinical Trials Group, Astex Pharmaceuticals, and Astex Pharmaceuticals, Inc.
Summary for AT7519
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 278 |
| WIPO Patent Applications | 110 |
| Japanese Patent Applications | 53 |
| Clinical Trial Progress | Phase 2 (2012-07-24) |
| Vendors | 70 |
Recent Clinical Trials for AT7519
| Title | Sponsor | Phase |
|---|---|---|
| Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | National Cancer Institute (NCI) | Phase 1 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | Astex Pharmaceuticals | Phase 2 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | Astex Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for AT7519
Top disease conditions for AT7519
Top clinical trial sponsors for AT7519
US Patents for AT7519
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
